JAZZ vs GRAB Comparison

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Founded in 2012, Grab provides ride-hailing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging a commission to both sides. Grab has a leading market share and derives over 70% of its revenue from its core businesses, ride-hailing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2025. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.